Health · 42 views
Combination therapy improves progression-free survival for patients with metastatic dMMR colorectal cancer
Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab (Tecentriq)…
Summary
Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab (Tecentriq) plus modified FOLFOX6 and bevacizumab (Avastin), compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published in the Journal of Clinical Oncology . The combination also produced higher response rates and substantially reduced primary disease progression.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- New technology advances understanding of eye pressure and glaucomaContinue reading
- Weekly cisplatin fails to show fewer serious side effects in p16-negative head and neck cancerContinue reading
- Alan Alda on fighting Parkinson's with laughterContinue reading
- Medicare for All remains key pressure point for Democrats ahead of midtermsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow